GLOW is a market label, not an approved drug product, applied by suppliers to a lyophilized vial holding three separate peptides: GHK-Cu, BPC-157, and TB-500. No pharmacopeial monograph or regulator-published definition fixes the composition, so the milligram quantities are whatever the individual seller declares on its own label. The most frequently listed configuration totals roughly 70 mg of peptide per vial, which is why the product often carries a trailing number such as 70.
GLOW is a supplier label rather than an approved formulation, and its most commonly declared configuration is GHK-Cu at roughly 50 mg with BPC-157 and TB-500 at roughly 10 mg each, summing to about 70 mg of supplier-declared, untested peptide per vial.
Three named compounds recur across essentially every listing that uses this label, though the powder in the vial is not all peptide. The naming of TB-500 is where catalogs are least precise, since it is routinely called thymosin beta-4 even though it is a much shorter synthetic fragment of that protein.
Every GLOW listing centers on the same three compounds, GHK-Cu, BPC-157, and a thymosin beta-4 fragment sold as TB-500, while the powder also carries non-peptide acetate and bulking mass that the label rarely separates out.
No primary source documents an origin for the name, and it is neither a registered pharmaceutical trade name nor an acronym with an authoritative expansion. What the record shows is a term that appeared in research-chemical catalogs and user communities and then spread by imitation, each new seller copying the convention from the ones already using it. The word itself gestures at a cosmetic skin outcome, which is a marketing choice rather than a statement of contents.
No primary source, regulator, or manufacturer defines the GLOW name; it spread by seller imitation as marketing that gestures at a cosmetic skin effect, so the name identifies no fixed formulation and carries no definitional authority.
The trailing number in a name such as GLOW 70 conventionally refers to the summed milligrams of peptide in the vial, not to any single ingredient. Names built on 50 or 80 generally hold the two 10 mg components steady and move the copper tripeptide up or down. A subtlety labels rarely resolve is whether a figure is net peptide or gross acetate-salt powder, so a vial marked 10 mg may hold less than 10 mg of the peptide itself.
| Component | GLOW 50 | GLOW 70 | GLOW 80 |
|---|---|---|---|
| GHK-Cu | ~30 mg | ~50 mg | ~60 mg |
| BPC-157 | ~10 mg | ~10 mg | ~10 mg |
| TB-500 | ~10 mg | ~10 mg | ~10 mg |
The number in a name like GLOW 70 refers to the total declared milligrams in the vial, with BPC-157 and TB-500 typically fixed near 10 mg each while GHK-Cu ranges from roughly 30 mg in a 50 to 60 mg in an 80.
Suppliers do not use the same ratio, and nothing requires them to. The two smaller components tend to cluster at 10 mg each because that is the convention the market settled into for those peptides sold singly, while the copper tripeptide is where the real spread appears across listings that all carry the same product name.
No monograph or approved reference fixes the ratio, so while BPC-157 and TB-500 cluster near 10 mg, GHK-Cu ranges from roughly 30 mg to 60 mg across vials sharing the same name, meaning two people on the same-named product may receive very different amounts of the dominant component.
Each component carries its own separate literature, and the honest answer about the blend is that the literature stops at the single agents. No published study appears to test this three-component combination as a combination, so any account of what the blend does as a whole is inference stacked on single-agent preclinical data rather than measurement. That gap also leaves the interaction question unanswered rather than answered favorably.
The three components carry three separate evidence records, strongest for topical GHK-Cu and thinnest for the TB-500 fragment, and no published study tests the combination itself, so any claim about what the blend does as a whole is inference from single-agent preclinical data rather than measurement.
The label states a mass and the syringe measures a volume, so the number that actually matters is the mass divided by the diluent volume. A dose expressed in syringe units means nothing without the reconstitution volume attached, and on a 100-unit insulin syringe 10 units equals 0.1 mL, the conversion most dosing discussion silently assumes. The errors that bite in practice are compounding ones: a misremembered volume, a unit-to-milliliter slip, or a label figure that was never independently verified.
Concentration is the labeled mass divided by the diluent volume, so a 50/10/10 vial reconstituted with 2 mL delivers 2.5 mg, 0.5 mg, and 0.5 mg per 0.1 mL while the same vial with 5 mL delivers 1 mg, 0.2 mg, and 0.2 mg, and the fill-locked ratio moves all three together.
Confirming a blend means quantifying three different molecules in one sample, a harder problem than checking a single peptide, and it exposes the gap where most buyers are misled: purity and quantity are different claims. A certificate reporting 99 percent purity says the material present is mostly the intended peptide and says nothing about whether the vial holds the 50 mg its label declares. Seller-supplied certificates compound the problem, since they certify a laboratory the seller selected on a lot the seller nominated.
Purity and quantity are separate claims, and a 99 percent purity certificate says nothing about whether a vial holds its declared 50 mg; independent assays of open-market research peptides have repeatedly found content deviating from labels in both directions, sometimes with purity far below claim or elemental impurities above accepted limits for injectables.
None of the three is an FDA-approved drug for injection in humans, and combining three unapproved substances creates no new regulatory status, so the blend inherits the status of each component. When the FDA reviewed nominated bulk substances for 503A compounding, both BPC-157 and the thymosin beta-4 fragment sold as TB-500 landed in the category reserved for substances that raise significant safety risks; the nominations were later withdrawn, which does not reopen the pathway. FDA warning letters in this market have typically targeted the human-use claim rather than the molecule itself.
None of the three peptides is FDA-approved for human injection, none qualifies for 503A compounding by any of the statute's three routes, and the products remain on the market only under research-use-only labeling that declares them not for human use.
The tradeoff is convenience against control, and the convenience is smaller than it first looks. A single vial means one reconstitution and one draw, and blended vials are often priced below the sum of three separate ones, which is the argument sellers lead with. Against that, the seller-chosen ratio is frozen at fill, so the amounts move together, attribution of any effect or reaction is lost, and the copper tripeptide's chemical activity in a shared solution goes unstudied.
| Criteria | Premixed blend | Separate vials |
|---|---|---|
| Handling | One reconstitution, one draw | Three of each |
| Ratio control | Fixed at fill, unchangeable | Each component set independently |
| Attribution | Three variables move at once | Sequential introduction possible |
| Compatibility | Three peptides share one unstudied solution | Each stored and mixed on its own |
A premixed blend trades away all ratio control and attribution for one fewer reconstitution, since its seller-set proportions are frozen at fill and cannot be adjusted, while three separate vials preserve independent dosing, sequential introduction, and the ability to isolate which component caused an effect.
Educational use only. This article describes what the published scientific and clinical literature reports about GLOW blend. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
